This Report provides an up-to-date assessment of current directions and prospects in the angiogenesis modulators field. After three decades of research in this field, human trials of angiomodulatory compounds are at last beginning to yield commercial products with proven efficacy. Many diverse drugs targeting angiogenesis are in clinical development. This report offers a comprehensive review of targets for angiogenesis modulation, identifies the most promising approaches, and assesses the prospects for angiogenesis modulators in different therapeutic areas.
The Report highlights commercial opportunities for angiogenesis inhibitors such as new therapeutic modalities in cancer, ophthalmic diseases, vascular skin diseases, and chronic inflammatory diseases. It also assesses current and potential applications of angiogenesis stimulators in tissue revascularization.
